• Data from key trials will aid in increasing scientific understanding of ESUS and CVT
• RESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa® vs ASA

(AETOS Wire) -- Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®, will be presented at the upcoming World Stroke Congress in"...

Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has announced its entry into the oncology market through a license and supply agreement with Russia’s leading biotechnology company, BIOCAD.

Julphar will be partnering with BIOCAD and Health Authorities to register three leading specialized products to the UAE, which are used to treat breast cancer, B-cell non-Hodgkin's"...

The Palestinian Union of Social Workers and Psychologists has issued a formal statement earlier this week condemning the decision of the International Association for Relational Psychoanalysis and Psychotherapy (IARPP) to hold its 2019 annual conference in Israel. In December 2017, an international group of mental health clinicians requested that the IARPP reconsider that plan, but IARPP refused. In January 2018, three organizations, the USA-Palestine Mental Health Network, the UK-Palestine Mental Health Network, and Jewish"...

Jehad International Medical Clinic (JIMC), a specialised medical service provider in Dubai, has achieved accreditation by the Joint Commission International (JCI) for the third time. This accreditation is for the medical facility’s commitment to demonstrate compliance with the global organisation’s quality and patient safety standards.

JIMC is an advanced clinic for the treatment of hemorrhoids and"...

Hallstar, a specialty chemical company headquartered in Chicago, has been awarded the 2018 ITEHPEC Innovation Silver Prize for its anti-blue light, anti-pollution, eco-designed active, BLUE Oléoactif®.

The ITEHPEC (Inovação e Tecnologia em Higiene Pessoal, Perfumaria, e Cosméticos) Innovation Award, created in 2005 by Brazil’s most important personal care association, recognizes suppliers that contribute to"...

When a 40-year-old, Maryam, an Arab national was diagnosed with advanced stage breast cancer, she found herself in the hardest battle of her life. Maryam discovered her condition when she visited her doctor for a regular check-up. What came next, left her devastated. She was diagnosed with cancer, which dwelled in her for several months. To add to her woes, what came next was even more distressing. Her breast surgeon suggested a mastectomy - amputating the entire breast to treat the cancer. While the pain of cancer was not"...

The city of Haifa has the highest rate of cancer in Israel, Israeli Ministry of Health and Israel Cancer Association announced in a report yesterday.

According to the report, patients in Haifa suffer from lung, breast, prostate and intestine cancer nine to 14 per cent more than people around Israel.

Cancer is the leading cause of death in Israel since 1999, account for"...

FOR MEDICAL AND TRADE MEDIA ONLY

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for esketamine nasal spray, a glutamate receptor modulator, for treatment-resistant depression (TRD) in adults with Major Depressive Disorder (MDD) who have not responded to at least two different treatments with antidepressants"...

MinIT, a rapid analysis and device control accessory for nanopore DNA sequencing, is now arriving with genomics researchers. Scientists will use it to run the MinION DNA/RNA sequencer, opening up high-throughput, real-time nanopore sequencing to more users in more locations.

MinIT is equipped with a state-of-the-art NVIDIA AGX system, to enable real-time, high-throughput data analysis. It is preconfigured with software for quick setup and easy operation"...

• Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of empagliflozin (marketed as Jardiance®) on life expectancy of adults with type 2 diabetes and cardiovascular disease1

Today, the journal Circulation published novel results based on data from the landmark EMPA-REG OUTCOME® trial, which suggest that treatment with empagliflozin positively impacts life expectancy in"...